Ian Schofield

Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
French Patients To Get Pre-Approval Access To Bayer’s Vitravki
EU ‘Big Data’ Report: Big Opportunities – And Big Challenges
EU regulators have produced the first fruits of their ambitious “big data” project aimed at ensuring that the EU drug regulatory system can make full use of the rapidly increasing volume and complexity of data being gathered across multiple settings in the healthcare area.
UK Industry Skeptical Of Govt’s No-Deal Brexit Filing Expectations
The BioIndustry Association’s latest Brexit webinar looked at issues such as companies’ drug filing strategies in a no-deal scenario as well as the costs that industry is likely to incur as a result of changes to regulatory processes.
Australia Considers Identifying Drugs Filed For Approval
BIA ‘Reassured’ On Post-Brexit SPC Regime But Data Exclusivity Concerns Remain
The government has said it is prepared to discuss the terms of supplementary protection certificates under a UK-only regime if there is a no-deal Brexit, but concerns also linger over the start dates for regulatory data protection.
UK's NICE Rejects US Industry Attack On Its HTA Methods
The National Institute for Health and Care Excellence does not agree with assertions by the US pharmaceutical industry that its HTA process are “rigid” and “fail to recognize the full value of innovative medicines.”